Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

R&D Systems, part of Bio-Techne | Catalog # BT9269

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
BT9269-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems CHO-derived Recombinant Human CD19 Fc Chimera Biotinylated Protein (BT9269)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Structure / Form

Disulfide linked homodimer, Biotinylated via amines

Conjugate

Biotin

Applications

Bioactivity

View all CD19 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein
Human CD19
(Glu21-Lys291)
Accession # P15391		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu21

Predicted Molecular Mass

57 kDa

SDS-PAGE

75-90 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human CD19 Fc Chimera binds to Human CD19 Antibody (Catalog # MAB4867) with an ED50 of 25.0-250 ng/mL.

Scientific Data Images for Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

Biotinylated Recombinant Human CD19 Fc Chimera Protein Binding Activity.

Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human CD19 Fc Chimera (Catalog # BT9269) binds to Human CD19 Antibody (MAB4867) with an ED50 of 25.0-250 ng/mL.

Biotinylated Recombinant Human CD19 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Biotinylated Recombinant Human CD19 Fc Chimera Protein (Catalog # BT9269) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-90 kDa and 150-180 kDa, respectively.

Formulation, Preparation and Storage

BT9269
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD19

CD19 protein is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). The CD19 protein associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors. Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has proven effective in many different cancers. The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials. Mature human CD19 protein consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19.

References

  1. Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
  2. Tedder, T.F. et al. (1997) Immunity 6:107.
  3. Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
  4. Rickert, R.C. et al. (1995) Nature 376:352.
  5. Engel, P. et al. (1995) Immunity 3:39.
  6. Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
  7. Deaglio, S. et al. (2007) Blood 109:5390.
  8. Bradbury, L. et al. (1992) J. Immunol. 149:2841.
  9. Krop, I. et al. (1996) J. Immunol. 157:48.
  10. O'Rourke, L.M. et al. (1998) Immunity 8:635.
  11. Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
  12. Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
  13. Carter, R.H. and D.T. Fearon (1992) Science 256:105.

Alternate Names

CD19, CVID3, Leu-12

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Gene Symbol

CD19

Additional CD19 Products

Product Documents for Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CD19 Fc Chimera Biotinylated Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.